2025
Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice
Sharma L, Singh R, Ngeow C, van der Geest R, Duray A, Tolman N, McVerry B, Dela Cruz C, Alcorn J, Bain W, Robinson K. Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice. Physiological Reports 2025, 13: e70232. PMID: 39921246, PMCID: PMC11805821, DOI: 10.14814/phy2.70232.Peer-Reviewed Original ResearchConceptsMurine model of influenzaIL-6 deletionMRSA pneumoniaModel of influenzaInflammatory cell recruitmentIL-6Interferon-stimulated genesMurine modelCell recruitmentJAK inhibitionElevated levels of IL-6Tissue injuryLevels of IL-6IL-6 deficiencyJAK inhibitor baricitinibSuppression of cytokinesLimit tissue injuryLung tissue injurySecondary bacterial infectionInfluenza infectionJAK/STAT signaling pathwayBaricitinib treatmentInhibitory therapyClinical efficacyBacterial burden
2024
Early antiviral use and supplemental oxygen decrease the risk of secondary bacterial infections: a multi-centre, nested, case–control study
Zhu Y, Hu H, Guo X, Zhang H, Li D, Dela Cruz C, Xie W, Xie L, Sharma L, Chang D. Early antiviral use and supplemental oxygen decrease the risk of secondary bacterial infections: a multi-centre, nested, case–control study. Journal Of Hospital Infection 2024, 156: 87-95. PMID: 39701496, DOI: 10.1016/j.jhin.2024.12.005.Peer-Reviewed Original ResearchConceptsRisk of secondary bacterial infectionIncidence of secondary bacterial infectionSecondary bacterial infectionAge-adjusted Charlson Comorbidity IndexCase-control studyPropensity-score matchingBacterial infectionsCOVID-19 patientsParenteral nutritionSupplemental oxygenTreatment strategiesAssociated with significant protectionAssociated with decreased incidenceAssociated with increased incidenceConditional logistic regression analysisSusceptibility to secondary bacterial infectionsAssociated with protectionCharlson Comorbidity IndexLogistic regression analysisAssociated with significant increasesAntiviral useGastric tubeAntibacterial therapyComorbidity indexIntravenous injectionClinical features and multiomics profiles indicate coagulation and platelet dysfunction in COVID-19 viral sepsis
Xiao Z, Lin M, Song N, Wu X, Hou J, Wang L, Tian X, An C, Dela Cruz C, Sharma L, Chang D. Clinical features and multiomics profiles indicate coagulation and platelet dysfunction in COVID-19 viral sepsis. IScience 2024, 27: 110110. PMID: 38974472, PMCID: PMC11225851, DOI: 10.1016/j.isci.2024.110110.Peer-Reviewed Original ResearchViral sepsisCausative agent of sepsisAgent of sepsisCases of sepsisSusceptibility to secondary bacterial infectionsNon-sepsis patientsSecondary bacterial infectionPlatelet activation pathwaysMetabolomic characteristicsPlatelet dysfunctionSepsis phenotypesClinical featuresSystemic disease phenotypeSepsis patientsSepsisCOVID-19 pathologyBacterial infectionsProteomic signatureDisease phenotypeComplement proteinsBacterial pathogensProteomic dataActivation pathwayFunctional consequencesPathway proteins
2023
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Frontiers In Immunology 2023, 14: 1116131. PMID: 37646038, PMCID: PMC10461092, DOI: 10.3389/fimmu.2023.1116131.Peer-Reviewed Original ResearchConceptsClinical managementAppropriate host immune responseSevere acute pneumoniaMultiple organ failureCOVID-19 pathogenesisSecondary bacterial infectionLower respiratory systemSpecific pathogenic mechanismsHost immune responseLife-threatening consequencesCOVID-19SARS-CoV-2Spread of infectionOrgan failureAcute pneumoniaExcessive inflammationInfected subjectsSystemic diseaseProtease TMPRSS2Mild infectionImmune responseHealthcare threatPathogenic mechanismsTherapeutic paradigmBacterial infectionsCoronaviruses, Lysosomes, and Secondary Bacterial Infections: Coronaviruses Outsmart the Host
Peng X, Dela Cruz C, Sharma L. Coronaviruses, Lysosomes, and Secondary Bacterial Infections: Coronaviruses Outsmart the Host. DNA And Cell Biology 2023, 42: 189-193. PMID: 36763591, DOI: 10.1089/dna.2023.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSecondary bacterial infectionCellular homeostatic functionsHomeostatic functionsExtensive cell deathBacterial infectionsLysosomal lumenLysosomal machineryKey organellesLysosomal pathwayUnique adaptationsExit cellsSevere acute respiratory syndrome coronavirus 2Cell deathCellular componentsAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Pathogen killingCoronavirus disease 2019LysosomesLysosomal enzymesLysosomal environmentCoronavirus 2Host immunityCausative agent
2022
Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction.
Peng X, Kim J, Gupta G, Agaronyan K, Mankowski MC, Korde A, Takyar SS, Shin HJ, Habet V, Voth S, Audia JP, Chang D, Liu X, Wang L, Cai Y, Tian X, Ishibe S, Kang MJ, Compton S, Wilen CB, Dela Cruz CS, Sharma L. Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction. The Journal Of Immunology 2022, 209: 1314-1322. PMID: 36165196, PMCID: PMC9523490, DOI: 10.4049/jimmunol.2200198.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Bacterial infectionsMouse modelCoronavirus infectionLysosomal dysfunctionMajor health care challengeLung immune cellsLung tissue damageSecondary bacterial infectionImpair host immunityIL-1β releaseHealth care challengesCell deathPyroptotic cell deathBacterial killing abilityIL-1βBacterial clearanceImmune cellsSecondary infectionHost immunityAlveolar macrophagesTissue damageΒ-coronavirusStructural cellsCare challenges
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply